The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis.

// Wei Nie 1 , Xia Tao 2 , Hua Wei 2 , Wan-sheng Chen 2 , Bing Li 1 1 Department of Respiratory Medicine, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai 200003, China 2 Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China Correspondence to: Wan-sheng Chen, e-mail: chenws126@126.com Bing Li, e-mail: bing_li1962@163.com Keywords: Bcl-2-like protein 11, non-small cell lung cancer, epidermal growth factor receptor, tyrosine kinase inhibitor Received: May 21, 2015      Accepted: July 15, 2015      Published: July 27, 2015 ABSTRACT The prognostic value of Bcl-2-like protein 11 (BIM) deletion polymorphism for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) treatment in non-small cell lung cancer (NSCLC) were reported. However, the results remained controversial. Thus, we did this systematic review and meta-analysis to address this issue. Databases including PubMed, Embase, and the Cochrane Register of Controlled Trials were searched to find relevant studies. The primary outcome was progression-free survival (PFS). Five retrospective cohort studies were included. All of the studies were conducted in Asian population ( n = 951). The methodological quality of all included studies was high. Compared with BIM wild type, BIM deletion polymorphism was predictive of shorter PFS in NSCLC patients who were treated with EGFR-TKIs (adjusted HR = 2.38, 95% CI 1.66–2.41, P < 0.001). In conclusion, the BIM deletion polymorphism was associated with poor response in NSCLC patients who received EGFR-TKIs treatment.